Mast Therapeutics, Inc. (NASDAQ:SVRA) had its target price raised by stock analysts at Canaccord Genuity from $18.00 to $25.00 in a research report issued on Monday. The firm presently has a “buy” rating on the stock. Canaccord Genuity’s target price points to a potential upside of 169.40% from the company’s previous close.

The analysts wrote, “We see Savara‚Äôs work in NTM as meaningfully differentiated from other therapies as Molgradex is a non- antibiotic approach to treating lung NTMs and the product has potential to show efficacy in especially-hard-to-treat MABS infections where there are no viable pharmacological therapies available.””

Other equities research analysts have also issued reports about the stock. Roth Capital reaffirmed a “buy” rating and set a $40.00 price target on shares of Mast Therapeutics in a report on Wednesday, September 27th. Jefferies Group LLC initiated coverage on shares of Mast Therapeutics in a report on Friday, September 22nd. They set a “buy” rating and a $20.00 price target for the company. Zacks Investment Research raised shares of Mast Therapeutics from a “hold” rating to a “buy” rating and set a $9.50 price target for the company in a report on Tuesday, September 19th. Finally, JMP Securities initiated coverage on shares of Mast Therapeutics in a report on Monday, September 11th. They set an “outperform” rating and a $20.00 price target for the company. Five analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus target price of $22.90.

Mast Therapeutics (SVRA) traded up 7.91% during midday trading on Monday, hitting $9.28. 181,828 shares of the stock traded hands. The company’s market cap is $224.60 million. Mast Therapeutics has a one year low of $4.60 and a one year high of $16.23. The company’s 50-day moving average is $8.92 and its 200-day moving average is $6.73.

WARNING: “Mast Therapeutics, Inc. (SVRA) Given New $25.00 Price Target at Canaccord Genuity” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at

In other news, Director Yuri Pikover purchased 50,000 shares of the stock in a transaction that occurred on Friday, October 27th. The stock was acquired at an average cost of $7.85 per share, with a total value of $392,500.00. Following the acquisition, the director now owns 150,000 shares in the company, valued at $1,177,500. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 6.93% of the stock is currently owned by company insiders.

About Mast Therapeutics

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with's FREE daily email newsletter.